We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Inhibiting Enzyme Activity Overcomes Cell Differentiation Blockade

By LabMedica International staff writers
Posted on 26 Sep 2016
Print article
Image: A photomicrograph of bone marrow aspirate showing acute myeloid leukemia (AML) (Photo courtesy of Wikimedia Commons).
Image: A photomicrograph of bone marrow aspirate showing acute myeloid leukemia (AML) (Photo courtesy of Wikimedia Commons).
Inhibition of the enzyme dihydroorotate dehydrogenase (DHODH) was found to stimulate differentiation of acute myeloid leukemia (AML) cells, which reduced the cancer cell burden and promoted survival in human and mouse models.

AML is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. Symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. AML progresses rapidly and is typically fatal within weeks or months if left untreated.

Investigators at the Harvard Medical School (Boston, MA, USA) screened more than 330,000 compounds while searching for new drugs to treat AML. They identified a dozen compounds that forced the leukemic cells to differentiate, and of those, 11 blocked the metabolic enzyme dihydroorotate dehydrogenase (DHODH). This enzyme, which is encoded by the DHODH gene on chromosome 16, catalyzes the fourth enzymatic step, the ubiquinone-mediated oxidation of dihydroorotate to orotate, in de novo pyrimidine biosynthesis. DHODH is a mitochondrial protein located on the outer surface of the inner mitochondrial membrane (IMM). Inhibitors of this enzyme are used to treat autoimmune diseases such as rheumatoid arthritis.

The investigators reported in the September 15, 2016, online edition of the journal Cell that in vivo treatment with DHODH inhibitors reduced leukemic cell burden, decreased levels of leukemia-initiating cells, and improved survival of mice with AML and mice injected with human leukemia cells. These results demonstrated the role of DHODH as a metabolic regulator of differentiation and pointed to its inhibition as a strategy for overcoming differentiation blockade in AML.

"We need desperately to find new therapies, not only for the 20,000 people diagnosed with AML every year, but for all cancers," said senior author Dr. David Scadden, professor of medicine at Harvard Medical School. "We think that an approach to overcome the differentiation blockade of cancer may be a strategy with broad application and one we should explore for other cancer types."

Related Links:
Harvard Medical School


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.